Drug Profile

MTS 004

Alternative Names: MTS 004 ODT; MTS‑004

Latest Information Update: 05 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator METiS Pharmaceuticals
Class Behavioural disorder therapies; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase III Emotional lability

Most Recent Events

05 Nov 2025 Efficacy and adverse events data from a phase III trial in Emotional lability released by METiS Pharmaceuticals
23 Oct 2025 METiS Pharmaceuticals plans to submit a New Drug Application (NDA) for MTS 004 to the National Medical Products Administration (NMPA) in Emotional lability in 2026
01 Aug 2022 Market approval for MTS 004 is anticipated in China in 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com